SequelSEC

CHINA PHARMA HOLDINGS, INC. CPHI

Pharmaceutical Preparations · CIK 0001106644 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$3.91M
Fiscal year ended 2026-06-30
Operating income
-$4.38M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$4.29MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.11Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue1.0×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity0.2×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Gross margin-3.2%3th
Current ratio0.32x9th
R&D / revenue6.8%9th
FCF margin2.1%72th
Revenue YoY growth-8.5%35th
Operating margin-78.2%62th
Net margin-76.9%57th
CapEx / revenue1.4%46th

CHINA PHARMA HOLDINGS, INC. (CPHI) reported revenue of $3.91M and net income of -$4.47M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from CHINA PHARMA HOLDINGS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

CHINA PHARMA HOLDINGS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$3.91M
Cost of revenue$3.45M
Gross profit$460.17K
Operating income-$4.38M
Net income-$4.47M
Research & development$333.26K
Weighted-average diluted sharesUnavailable
Pretax income-$4.47M
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$4.11M
Selling & marketingUnavailable

Balance

CHINA PHARMA HOLDINGS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$304.87K
Total assets$44.71M
Current assets$2.01M
Total liabilities$8.53M
Current liabilities$7.68M
Total equity incl. NCI$36.18M
Temporary (mezzanine) equityUnavailable
Inventory$1.36M
Accounts receivable$181.62K
GoodwillUnavailable
Long-term debtUnavailable
Accounts payableUnavailable

Cash flow

CHINA PHARMA HOLDINGS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$140.49K
Capital expendituresUnavailable
Investing cash flowUnavailable
Financing cash flow-$154.01K
Net change in cash-$320.16K
Stock-based compensationUnavailable
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$2.94M

Derived

CHINA PHARMA HOLDINGS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross margin11.8%
Operating margin-111.8%
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio0.26x
Revenue YoY growth-11.0%
Net margin-114.3%
R&D / revenue8.5%
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CPHI in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-04-01View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.